Montefar is commonly used across conditions characterized by periods of heightened symptoms in the respiratory and allergic domains. The medication is relevant for easing challenging manifestations related to asthma, allergic rhinitis, and breathing difficulties associated with physical exertion.

It is relevant for managing the following conditions: chronic asthma, symptomatic seasonal or perennial allergic rhinitis, and exercise-induced bronchoconstriction. The therapeutic approach is applied in managing symptom clusters that may become intense or disruptive, such as recurrent wheezing, persistent coughing, and sneezing.

“The primary goal is to provide support that helps ease the overall symptom burden for long-term control.”

Quick Fact: Supportive Management

Condition	Symptom Focus	Core Benefit
Asthma	Wheezing, Coughing, Chest tightness	Support for assisting with functional stability.
Rhinitis	Nasal congestion, Sneezing	Assists in supporting comfort during symptomatic periods.

The medication may assist with managing episodes of sudden symptom escalation associated with physical exertion, contributing to an improved ability to cope more steadily with symptom fluctuations during physical activity.

Regulatory References

1. NIH MedlinePlus overview of Montelukast

Who can and cannot use Montefar? — Official Regulatory Information

The eligibility profile for Montefar (montelukast sodium) is strictly defined by regulatory health authorities and outlines specific populations who must avoid the medicine, as well as those for whom use is restricted or conditional.

Absolute Exclusions

Montefar is contraindicated and must not be used by patients with a known hypersensitivity or allergy to montelukast or any ingredient in the product. The medicine is also not indicated for the treatment of an acute asthma attack or status asthmaticus.

Conditional and Restricted Use

For the treatment of allergic rhinitis (seasonal or perennial), the use of this medicine is restricted. It should only be used in patients who have had an inadequate response to or intolerance of alternative therapies.

Age-Based Eligibility

The minimum age for use varies significantly by the condition being treated:

Indication	Minimum Eligible Age
Chronic Asthma	12 months
Exercise-Induced Bronchoconstriction	6 years
Allergic Rhinitis	6 months to 2 years

Special Populations

Data from studies have not identified a drug-associated risk of adverse outcomes in pregnancy. However, it is unknown if the active ingredient is excreted in human milk. No dosage adjustments are specified for patients with renal or mild-to-moderate hepatic impairment.

The interaction profile for Montefar is defined by its metabolism through hepatic Cytochrome P450 enzymes (CYP3A4, CYP2C8, and CYP2C9), which governs its pharmacokinetic interactions. Co-administration with the CYP2C8 and CYP2C9 inhibitor Gemfibrozil results in a significant pharmacokinetic effect, formally documented as increasing Montelukast's total systemic exposure (AUC) by up to 4.4-fold.

Conversely, co-administration with potent enzyme inducers, such as Phenobarbital or Rifampicin, is documented to decrease Montelukast systemic exposure, with Phenobarbital causing a reduction in AUC of approximately 40%. Caution regarding these inducers is specifically noted for the pediatric population.

In contrast, Montelukast is documented as having no clinically important effect on the pharmacokinetics of several commonly co-administered medicines, including Theophylline, Warfarin, or Oral Contraceptives.

Regulatory labeling imposes a crucial pharmacodynamic restriction: patients with established aspirin sensitivity must continue to avoid Aspirin or Non-Steroidal Anti-Inflammatory Agents (NSAIDs) while taking Montefar. Regarding food interactions, a high-fat meal decreases the rate of absorption, but is officially documented as having no effect on the overall extent of systemic exposure (AUC). The official documentation does not list any mandatory timing separation requirements for co-administered medicinal products.

Blocking the Cysteinyl Leukotriene Receptor (CysLT1)

Montefar functions as a selective leukotriene receptor antagonist by binding with high affinity to the Cysteinyl Leukotriene type 1 (CysLT1) receptors. These receptors are expressed on various cells, including those in the airway smooth muscle and immune cells.

This binding blocks the activation of the receptor by the pro-inflammatory mediators, primarily the cysteinyl leukotrienes (LTC4, LTD4, LTE4). This molecular interaction interrupts the signal transduction cascade, suppressing subsequent cellular responses that contribute to inflammation.

Physiological Modulation

Preventing CysLT1 activation modifies the signaling dynamics that govern airway function. This includes the prevention of bronchoconstriction (airway smooth muscle contraction) and the decrease of vascular permeability, which limits fluid accumulation in the airway lining (edema). The resulting physiological change is the relaxation of bronchial smooth muscle and a reduction in airway wall edema. This mechanistic pathway decreases physical resistance encountered during respiration.

How Montefar is Used: Official Administration Guidelines

Montefar, containing the active ingredient Montelukast, is intended exclusively for oral administration. The medicine is utilized as a long-term controller and is taken on a once-daily schedule, establishing its use as continuous maintenance therapy. The dose is fixed and determined by the patient's age group, rather than being adjusted based on weight for chronic use.

---

Standard Dosing and Frequency

The standard regimen dictates that for asthma and concomitant allergic rhinitis, the dose should generally be taken in the evening. The medicine may be taken with or without food.

Age Group	Dosage Form	Daily Dose	Dosing Time Context
Adults and Adolescents (ge15 years)	Film-coated Tablet	10 mg	Typically evening
Pediatric (6–14 years)	Chewable Tablet	5 mg	Typically evening
Pediatric (2–5 years)	Chewable Tablet or Granules	4 mg	Typically evening

---

Use for Exercise-Induced Bronchoconstriction (EIB)

For prophylaxis of EIB, a single dose must be administered at least two hours prior to exercise. A patient already receiving a once-daily dose for chronic use should not take an additional dose for EIB within the same 24-hour period.

---

Handling Instructions

Montefar is supplied as film-coated tablets, chewable tablets, and oral granules. The chewable tablets must be chewed completely before swallowing. Oral granules must be administered within 15 minutes of opening the sachet and can be mixed with limited cold or room temperature soft foods or liquids, such as applesauce or baby formula. The mixture is intended for immediate intake and must not be stored for later use.

Research evidence / Overview of studies for Montefar

Evidence for use in Chronic Asthma

Research exploring the use of Montefar for chronic asthma involves numerous Randomized Controlled Trials (RCTs) and systematic reviews, spanning age groups from 12 months and older. The trials were used in research exploring how symptoms change over time, monitoring key measurements such as Forced Expiratory Volume in 1 second ( FEV1), which is a measure of lung function, and the patterns related to the frequency of acute episodes.

Studies report measurements of changes in FEV1 and data show patterns related to the use of rescue medication in the observed populations. However, some trials described patterns where the measured changes varied when compared to those observed with inhaled corticosteroids. Follow-up durations were limited in the core RCTs, meaning long-term effects are not fully established regarding the potential progression of lung function impairment based on core RCT data.

Evidence for use in Allergic Rhinitis

Research for allergic rhinitis is built primarily upon short-term (typically 2 to 4 weeks) Randomized Controlled Trials. Research examined outcomes related to physical discomfort, such as Total Nasal Symptom Scores (TNSS), focusing on aspects like nasal congestion and sneezing. Findings indicate patterns where short-term symptom patterns were observed in some studies to be similar to those of antihistamines. Regulatory bodies have noted that the use of this medicine may be reserved for individuals whose mild symptoms were not sufficiently addressed by or who cannot tolerate alternative medicines.

Evidence for Preventing Exercise-Induced Bronchoconstriction (EIB)

Studies employed RCTs using standardized exercise challenge protocols to reliably induce a temporary physiological imbalance. Research examined the primary outcome related to monitoring physiological strain, specifically the maximal drop in the functional measure of FEV1 after exercise.

Studies monitored responses over defined time intervals, and the data show patterns related to changes in temporary physiological imbalance following exercise challenges. Regulatory reviewers noted that the measured magnitude of these changes was described as modest.

Evidence Gaps and Research Uncertainties

Evidence quality varies across studies and the findings were mixed in certain comparisons. Post-marketing reports have described that adverse events was associated with the use of this medicine in some cases. Regulators have noted the need for additional context regarding adverse events and have further noted that the use of this medicine for mild allergic rhinitis may be reserved because certainty remains low that the benefits outweigh potential risks in mild conditions.

Key Studies & References

1. Global Initiative for Asthma Strategy Report (GINA)
2. Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) Guideline
3. Montelukast: reminder of the risk of neuropsychiatric reactions (MHRA Drug Safety Update)

Common questions about Montefar (FAQ)

---

Q: How long does it take for Montefar to start working for asthma symptoms?

Studies show that the active ingredient in Montefar is rapidly absorbed after oral administration. According to official product information, the maximum concentration of the medicine in the blood is typically reached in about 3 to 4 hours. This measure relates to how quickly the drug enters a patient's system.

---

Q: What are the instructions for mixing and administering Montefar oral granules?

Official guidelines allow for administration directly into the mouth or mixed with a small amount of cold or room temperature soft food, such as a spoonful of applesauce or mashed carrots. They can also be mixed with 5 mL (1 teaspoonful) of breast milk or baby formula. Any mixture must be consumed within 15 minutes of opening the sachet and must not be stored for later use.

---

Q: What should I do if I miss a dose of Montefar?

Official labeling advises that if a dose is missed, the patient should skip that dose and take the next scheduled dose at the regular time. Taking two doses at the same time to make up for a missed dose is not recommended.

---

Q: Can Montefar be taken in the morning instead of the evening?

Montefar is generally recommended to be administered once daily in the evening for asthma patients. Official regulatory documents note that no clinical trials have specifically evaluated the relative effectiveness of morning versus evening dosing for chronic asthma management. Patients should maintain the schedule prescribed by their healthcare provider.

---

Q: How should I dispose of expired Montefar?

Safe drug disposal practices should be followed according to local or national guidelines. Official guidance for medicine disposal often involves mixing the drug with an unappealing substance, such as used coffee grounds or cat litter, sealing it in a container, and placing it in the trash. It is important to remove all personal information from the packaging before discarding it.

How to Store and Dispose of Montefar?

This section describes the storage, handling, and disposal requirements strictly defined in official regulatory documents for the product containing Montelukast and Levocetirizine.

Official Storage Requirements

Condition	Requirement
Temperature	Store below 30°C or within the range of 10°C to 25°C.
Environment	Keep in a cool and dry place, protected from direct sunlight.
Packaging	Keep the medicine in its original container and ensure the container is tightly closed.
Child Safety	The product must be kept out of the sight and reach of children.

Disposal Instructions

Official regulatory guidance requires the safe disposal of any unused or expired medicine. Upon disposal, ensure the product is not consumed by children, pets, or other people. The medicine should be discarded according to recognized guidelines for pharmaceuticals.